PTX-200, Paclitaxel, Doxorubicin Hydrochloride, and Cyclophosphamide in Treating Patients With Stage IIB-IV Breast Cancer

NCT01697293 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

TERMINATED

Status

34

Enrollment

INDUSTRY

Sponsor class

Stopped criteria for continuing enrollment in Phase 2 portion was not met

Conditions

Breast Adenocarcinoma
Estrogen Receptor Positive
HER2/Neu Negative
Recurrent Breast Carcinoma
Stage IIB Breast Cancer
Stage IIIA Breast Cancer
Stage IIIB Breast Cancer
Stage IIIC Breast Cancer
Stage IV Breast Cancer

Interventions

DRUG: Cyclophosphamide
DRUG: Doxorubicin Hydrochloride
OTHER: Laboratory Biomarker Analysis
DRUG: Paclitaxel
PROCEDURE: Therapeutic Conventional Surgery
DRUG: Triciribine Phosphate

Sponsor

Prescient Therapeutics, Ltd.

Collaborators

[object Object]